PREMIER Biosoft and PamGene Form Alliance to Develop MLPA Array
News Feb 22, 2007
PREMIER Biosoft International has announced an alliance with PamGene International B.V. to develop a software product for designing custom MLPA® oligonucleotide probes for use with PamChip® microarrays.
PREMIER Biosoft International, a bioinformatics company, and PamGene International B.V., owner of patented technologies for second-generation microarray products, have come together to develop a software tool to design custom oligos for use in MLPA® based assays.
Multiplex Ligation-dependent Probe Amplification (MLPA®) is a method for assessing tens to hundreds of gene copy number changes, single-nucleotide polymorphisms (SNPs), insertions and deletions and methylation markers in genomic DNA in a single reaction tube.
PamGene’s microarray platform can detect and quantify all the MLPA® amplified products with a single array using its flow-through PamChip® microarrays and PamStation® systems.
The alliance will help MLPA® users design custom oligos for use with PamGene's microarrays. Currently, such a tool is not available to the users.
"I see great synergies between the two companies. I look forward to working with PamGene to develop such an innovative product", commented Kay Brown, V.P. Business Development and Marketing of PREMIER Biosoft.
Rinie van Beuningen, V.P. Business Development, PamGene International added, “With this software tool we are enabling researchers to quickly develop new multiplex genomic assays for use in research and diagnostics.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.